NeuroThera advances enrollment in SCI-210 autism trial toward 60-participant goal

NeuroThera Labs, a SciSparc Ltd. subsidiary, is advancing SCI-210, a proprietary CBD and CannAmide formulation, for autism spectrum disorder symptoms in children at Soroka Medical Center in Israel. The double-blind, randomized, placebo-controlled trial compares SCI-210 to CBD monotherapy, with primary endpoints including the ABC-C caregiver questionnaire and CGI-I clinician assessment, plus determining the optimal dose over a 20-week treatment. In the latest updates, six of the planned 60 participants had been enrolled in the study, with ongoing plans for commercialization in Israel if successful. Enrollment momentum continued, with 26 participants enrolled toward the 60-target as of 2026, reflecting collaboration with the National Autism Research Center in Israel. The company frames SCI-210 within a broader strategy to build a portfolio of neurological therapies and to pursue market introduction in Israel first, followed by additional markets. Overall, the reporting indicates steady progress in the ASD-focused SCI-210 program and a clear path toward potential commercialization contingent on clinical results.